| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 01/21/2009 | CN101348455A Aspartic acid specificity cysteine proteinase inhibitors and uses thereof |
| 01/21/2009 | CN101347614A Growth hormone formulations |
| 01/21/2009 | CN100453549C 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 01/21/2009 | CN100453115C Self-emulsifying agglomerant of oral polypeptide medicine |
| 01/20/2009 | US7479564 e.g. 6-ethyl-5-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-5H-[1,3]dioxolo[4,5-f]benzimidazole; prostaglandin E2 receptor antagonists; arthritis, hyperalgesia, uterine contraction, digestive peristalsis, awakeness, blood pressure, platelet function, bone metabolism, angiogenesis |
| 01/20/2009 | US7479504 Edg receptor agonists |
| 01/20/2009 | US7479486 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids |
| 01/20/2009 | US7479279 Use of cytokines of the TGF-β superfamily for the treatment, inhibition and/or diagnosis of skin related disorders |
| 01/20/2009 | CA2445519C Method for manufacturing a low dose pharmaceutical composition |
| 01/15/2009 | WO2009009173A2 Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases |
| 01/15/2009 | WO2009008727A2 Molecules for targeting compounds to various selected organs or tissues |
| 01/15/2009 | WO2009008461A1 Pharmaceutical composition for disease caused by proliferation of sex hormone sensitive cell |
| 01/15/2009 | WO2009007454A2 8-beta-substituted estratrienes as selectively active estrogens |
| 01/15/2009 | WO2009007396A1 Nonsteroidal progesterone receptor modulators |
| 01/15/2009 | US20090018208 Novel Succinate Salt of O-Desmethyl-Venlafaxine |
| 01/15/2009 | US20090018183 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands |
| 01/15/2009 | US20090018177 Propane-1,3-Dione Derivative or Salt Thereof |
| 01/15/2009 | US20090018133 Novel Adamantane Derivatives |
| 01/15/2009 | US20090018107 Novel composition to increase muscle strength |
| 01/15/2009 | US20090018085 Use of a GnRH antagonist peptide in the treatment of sex hormone-dependent diseases |
| 01/15/2009 | US20090018077 Fibroblast Growth Factor-Like Polypeptides |
| 01/15/2009 | US20090018076 Fibroblast Growth Factor-Like Polypeptides |
| 01/15/2009 | US20090018068 G-protein coupled receptors |
| 01/15/2009 | US20090017014 Compositions and methods for the treatment of immune related diseases |
| 01/15/2009 | CA2693048A1 Molecules for targeting compounds to various selected organs or tissues |
| 01/15/2009 | CA2692727A1 8-beta-substituted estratrienes as selectively active estrogens |
| 01/14/2009 | EP2014677A1 A-33 related antigens and their pharmacological uses |
| 01/14/2009 | EP2014672A1 8-beta-substituted estratrienes as selectively active estrogens |
| 01/14/2009 | EP2013185A1 Novel compounds |
| 01/14/2009 | EP1659918B1 Antibodies directed to parathyroid hormone (pth) and uses thereof |
| 01/14/2009 | EP1463728B1 Fused cyclic modulators of nuclear hormone receptor function |
| 01/14/2009 | EP1317443B1 Chemokine receptor binding heterocyclic compounds |
| 01/14/2009 | EP1115877B1 Polynucleotide constructs and uses thereof |
| 01/14/2009 | EP1107775B2 Composition containing pyrrolizidine-alkaloid-free petasites |
| 01/14/2009 | CN100450480C Aquogel type thiamazole plaster preparation |
| 01/13/2009 | US7476681 anticarcinogenic agent; prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, prostate, lung, pancreatic, colon, renal cancer, myeloid leukemia |
| 01/13/2009 | CA2301032C A method of preventing or treating estrogen-dependent diseases and disorders |
| 01/08/2009 | WO2007118198A8 2-METHYLENE-1α,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF |
| 01/08/2009 | US20090012149 Prodrug of an ice inhibitor |
| 01/08/2009 | US20090012122 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/08/2009 | US20090012083 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/08/2009 | US20090012073 N-aroyl cyclic amines |
| 01/08/2009 | US20090012068 Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors |
| 01/08/2009 | US20090011041 Compositions for Correcting Age Related Changes of a Human Endocrine System and Methods for Producing a Pharmaceutical Form Bases on Said Compositions |
| 01/08/2009 | US20090010925 Antibody variants |
| 01/07/2009 | EP2011877A2 Conjugates for the modulation of immune responses |
| 01/07/2009 | EP2011800A2 Inhibitors of caspase |
| 01/07/2009 | EP2010555A2 Method for preparing 4-[17beta -methoxy-17 -alpha methoxymethyl-3-oxoestra-4,9-dien-11beta -yl]benzaldehyde (e)-oxime (asoprisnil) |
| 01/07/2009 | EP2010540A1 Spiro-imidazo compounds |
| 01/07/2009 | EP2010217A2 Therapeutic method for glycaemic control |
| 01/07/2009 | EP1406641B1 Krill extracts for prevention and/or treatment of cardiovascular diseases |
| 01/07/2009 | CN100448994C Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, proteins encoded, and uses thereof |
| 01/07/2009 | CN100448874C N-aroyl cyclic amines |
| 01/07/2009 | CN100448870C 2-aminoquinoline derivative |
| 01/07/2009 | CN100448487C Method of treating estrogen receptor positive carcinoma |
| 01/06/2009 | US7473761 Therapy for metabolic disorders; polycystic kidney diseasel diarrhea; gastrointestinal disorders |
| 01/06/2009 | CA2423017C Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| 01/06/2009 | CA2387058C Injection vehicle for polymer-based formulations |
| 01/06/2009 | CA2379086C 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 01/06/2009 | CA2369504C Pyrazole compositions useful as inhibitors of erk |
| 01/06/2009 | CA2344470C Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues |
| 01/06/2009 | CA2333869C Mousse composition |
| 01/01/2009 | US20090005390 Novel quinuclidine derivatives and their use |
| 01/01/2009 | US20090005318 Controlled release composition and method of producing the same |
| 01/01/2009 | US20090004283 Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-Co-Glycolide Polymers |
| 01/01/2009 | US20090004237 B7-Like Molecules and Uses Thereof |
| 12/31/2008 | WO2009002427A2 Methods of synthesizing cinacalcet and salts thereof |
| 12/31/2008 | WO2009001817A1 COMPOUND HAVING 11β-HSD1 INHIBITORY ACTIVITY |
| 12/31/2008 | WO2008110868A3 Proliferated islets |
| 12/31/2008 | EP2007770A1 Imidazo compounds |
| 12/31/2008 | EP2007365A2 Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith |
| 12/31/2008 | EP1283735B1 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 12/31/2008 | CN101333256A Human antibodies that bind human il-12 and methods for producing |
| 12/31/2008 | CN101333174A N-bridged selective androgen receptor modulators and methods of use thereof |
| 12/31/2008 | CN101332229A Prunella plant extract, preparation method and use thereof |
| 12/31/2008 | CN101332174A Dihydrotestosterone external preparation and pharmaceutical use thereof |
| 12/31/2008 | CN100447154C Use of HMG fragments as anti-inflammatory agents |
| 12/31/2008 | CN100447141C Hetero-bicyclic crf antagonists |
| 12/31/2008 | CN100446769C Medicine releasing composition for improving steroid compound stability |
| 12/31/2008 | CA2691196A1 Methods of synthesizing cinacalcet and salts thereof |
| 12/31/2008 | CA2690847A1 Liquiritigenin and derivatives as selective estrogen receptor beta agonists |
| 12/30/2008 | US7470710 Such as 2-Benzofuranylmethyl-1-((5-(4-fluorophenyl)-2-methyl-thiazolyl) carbonyl)piperidine; obesity, type 2 diabetes, sleep disorders; strokes, blocking emetic response |
| 12/30/2008 | US7470687 Aryl oximes |
| 12/30/2008 | CA2412560C Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
| 12/30/2008 | CA2352676C Composition and method for treatment of symptoms associated with insufficient estrogen production |
| 12/30/2008 | CA2223720C Novel uses for thyroid hormones or thyroid hormone-like compounds |
| 12/25/2008 | US20080318944 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 12/25/2008 | US20080317833 Novel Anti-Inflammatory Androstane Derivatives |
| 12/24/2008 | WO2008111862A3 Methods and compositions for manipulating mammalian embryos |
| 12/24/2008 | EP2004619A1 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| 12/24/2008 | EP2004216A1 Agent for the treatment of hormone-dependent disorders and uses thereof |
| 12/24/2008 | EP2004168A1 Stable oral pharmaceutical composition containing thyroid hormone receptor agonists |
| 12/24/2008 | CN100445280C Glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors |
| 12/24/2008 | CN100445272C Non-steroidal (hetero) cyclically substd. acylanilides with mixed gestagen and androgen activity |
| 12/24/2008 | CN100444867C Utilization of extracts from iris plants, cimicifuga racemosa and tectorigenin as estrofen-like organ-selective medicament without uteroetropic effects |
| 12/23/2008 | US7468367 depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis/disorder; depressive neurosis/disorder, anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; sex disorder, sexual disorder; schizophrenia; manic depression; |
| 12/23/2008 | US7468362 Carbonate and carbamate modified forms of glucocorticoids in combination with β2 adrenergic agonists |
| 12/23/2008 | US7468361 For therapy of skin conditions selected from the group consisting of dermatitis, eczema, keratosis, lack of skin firmness, wrinkles, lack of dermal hydration and insufficient sebum secretion |
| 12/23/2008 | US7468276 Bloodless mammalian placenta for use in generating multipotent stem cells |
| 12/23/2008 | US7468181 Means and methods for the production of adenovirus vectors |